Another Delay: Ampligen for Chronic Fatigue Syndrome

"One year after the FDA rejected Ampligen (poly I:poly C12U), manufacturer Hemispherx Biopharma Inc. has asked for up to another year to resubmit data on its New Drug Application (NDA)."

Read more: Another Delay: Ampligen for Chronic Fatigue Syndrome:

With New Information Indicating Effectiveness of Ampligen

"Shareholders in Hemispherx Biopharma, Inc. (AMEX: HEB) have been waiting a considerable period of time for the specialty pharmaceutical company to deliver positive news regarding their Phase III trial involving the experimental therapeutic Ampligen."


Read more: With New Information Indicating Effectiveness of Ampligen:

Ampligen for XMRV-Positive Chronic Fatigue Syndrome

"The makers of the immune-modulating-drug Ampligen, Hemispherx Biopharma Inc., presented new data Sept. 8 at the first International Workshop on XMRV suggesting that the drug works differently in chronic fatigue syndrome patients depending on their XMRV status."

Read more: Ampligen for XMRV-Positive Chronic Fatigue Syndrome: